Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research Portal

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged

6 papers

TDX-2026-00006

Management of Thyroid Storm with Severe Asthma: A Community Peer-Reviewed Clinical Consensus on Non-Beta-Blocker Rate Control and Adjunctive Therapies

Thyroid storm represents a life-threatening endocrine emergency characterized by exaggerated manifestations of thyrotoxicosis. Rapid heart rate control is critical, typically achieved with beta-adrenergic receptor blockers. However, the presence of severe comorbid conditions, such as severe asthma, can contraindicate standard beta-blocker therapy, posing a significant clinical challenge. This paper synthesizes a clinical discussion from the tachyDx community peer-review platform regarding the optimal management strategy for a 28-year-old male presenting with thyroid storm and severe asthma, specifically focusing on rate control alternatives and comprehensive adjunctive treatments. Methods: This case-based discussion was initiated by a verified endocrinologist on a specialized clinical Q&A platform, attracting input from another verified physician and garnering 68 community peer votes. The methodology involved expert clinical opinion exchange, evaluation of therapeutic alternatives, and consensus building on a complex patient presentation. The final management approach, which led to a successful clinical outcome, was subsequently shared and validated. Results: The consensus approach involved intravenous diltiazem for heart rate control, achieving a reduction from 156 to 94 bpm within four hours without precipitating bronchospasm. The comprehensive thyroid storm regimen included propylthiouracil (PTU), saturated solution of potassium iodide (SSKI), hydrocortisone, and cholestyramine. This multifaceted intervention resulted in a dramatic clinical improvement, with the Burch-Wartofsky score decreasing from 55 to 20 within three days. Conclusions: Diltiazem emerges as a safe and effective alternative for rapid heart rate control in thyroid storm patients with severe asthma where beta-blockers are contraindicated. The case reinforces the importance of a multi-modal therapeutic strategy targeting hormone synthesis, release, peripheral conversion, and enterohepatic recirculation, tailored to individual patient comorbidities.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 68 votes 6 Apr 2026

TDX-2026-00005

Interpreting Elevated Cardiac Troponin in Chronic Kidney Disease: An Evidence-Based Framework from Community Peer Consensus

Background: The interpretation of elevated cardiac troponin levels in patients with chronic kidney disease (CKD) presents a significant diagnostic challenge in acute care settings. CKD patients frequently exhibit chronically elevated baseline troponin, complicating the differentiation between acute myocardial infarction (AMI), demand ischemia, and non-ischemic myocardial injury. This ambiguity often leads to diagnostic delays or inappropriate interventions, particularly in the context of atypical symptoms and a desire for early discharge. Methods: This consensus paper synthesizes expert opinions and clinical insights from a peer-reviewed discussion involving four verified physicians (emergency medicine, cardiology, nephrology, internal medicine) on the tachyDx platform, which garnered 73 community peer votes. The methodology involved structured responses to a clinical dilemma, followed by expert review and synthesis. Results: Key findings include the utility of an absolute delta troponin rise of ≥0.05 ng/mL over 3-6 hours, integrated with clinical context, to warrant urgent cardiac evaluation. High-sensitivity troponin assays were deemed more useful in CKD when serial measurements and CKD-specific cutoffs are applied. CT coronary angiography serves as a valuable gatekeeper for intermediate-risk patients with adequate renal function (eGFR ≥30 mL/min/1.73m²), while pharmacologic stress testing is preferred for advanced CKD. A structured risk stratification approach was developed, emphasizing the integration of ECG, hemodynamic status, and symptomology. Conclusions: An integrated, multi-modal approach, combining serial high-sensitivity troponin measurements with an absolute delta threshold, careful clinical assessment, and judicious use of advanced imaging, is crucial for accurate risk stratification and management of CKD patients with suspected acute coronary syndromes. Effective patient communication regarding diagnostic timelines is also vital.

4 contributors 73 votes 6 Apr 2026

TDX-2026-00004

Anticoagulation Strategies for Portal Vein Thrombosis in Cirrhotic Patients: A Community Peer-Reviewed Clinical Consensus

Background: Portal vein thrombosis (PVT) is a common complication of cirrhosis, significantly impacting patient outcomes and transplant candidacy. The management of PVT in cirrhotic patients is complex due to a rebalanced hemostatic system, making traditional coagulation parameters unreliable and raising concerns about both bleeding and thrombotic risks. This paper synthesizes expert opinions on anticoagulation strategies for incidental PVT in Child-Pugh B cirrhosis. Methods: This study leveraged a community peer-review platform, tachyDx, where a clinical scenario involving a 52-year-old male with Child-Pugh B cirrhosis and incidental main PVT was presented. Three verified specialist physicians contributed detailed responses, which were further peer-voted by 68 community members. The discussion focused on INR interpretation, choice of anticoagulant, duration of therapy, and indications for transjugular intrahepatic portosystemic shunt (TIPS). Results: Expert consensus highlighted that INR is an unreliable marker of hemostasis in cirrhosis, advocating for clinical assessment and potentially viscoelastic testing. Low molecular weight heparin (LMWH) was preferred over direct oral anticoagulants (DOACs) in Child-Pugh B cirrhosis due to limited safety data and hepatic metabolism concerns, with specific platelet count-based dosing recommendations. Anticoagulation for at least 6 months, or until liver transplant, was recommended for main PVT. TIPS was reserved for failed anticoagulation or complications of portal hypertension. The importance of ruling out pylephlebitis was also emphasized. Conclusions: The management of PVT in cirrhotic patients necessitates a nuanced, multidisciplinary approach. LMWH appears to be the preferred initial anticoagulant in Child-Pugh B cirrhosis, guided by clinical factors and platelet counts. Further research, particularly randomized controlled trials, is warranted to establish the long-term safety and efficacy of DOACs in this vulnerable population.

3 contributors 68 votes 6 Apr 2026

TDX-2026-00003

Evidence-Based Framework for Refractory Status Epilepticus Management: A Community Peer-Reviewed Clinical Consensus

Background: Refractory status epilepticus (RSE) represents a neurological emergency associated with significant morbidity and mortality, characterized by persistent seizure activity despite the administration of adequate doses of at least two antiepileptic drugs, including a benzodiazepine. Optimal management strategies for RSE, particularly regarding continuous infusion agents, electroencephalographic targets, and the timing of etiologic investigations, remain subjects of ongoing clinical debate and require expert consensus. Methods: This paper synthesizes expert opinions derived from a structured, community peer-reviewed clinical discussion on the tachyDx platform. Three verified physicians, specializing in neurology and critical care, contributed to a case-based scenario of a 32-year-old female presenting with new-onset RSE. Their responses underwent peer evaluation by 106 community physicians. Results: Consensus emerged on several critical aspects of RSE management. Midazolam infusion was favored over propofol as a first-line continuous agent due to concerns regarding Propofol Infusion Syndrome (PRIS). The initial electroencephalographic target was seizure suppression, with escalation to burst-suppression reserved for persistent seizures. Infusions were typically maintained for 24-48 hours post-seizure cessation. Ketamine was identified as a valuable second-line continuous infusion. Early immunologic workup, particularly for anti-NMDA receptor encephalitis, was strongly recommended in new-onset RSE without clear etiology. Meticulous hemodynamic and electrolyte management was emphasized. Conclusions: The synthesized expert consensus provides a practical, evidence-informed framework for managing RSE, highlighting the importance of a multidisciplinary approach, careful agent selection, individualized electroencephalographic targets, and prompt etiologic investigation, especially for autoimmune causes.

3 contributors 106 votes 6 Apr 2026

TDX-2026-00002

Optimizing SGLT2 Inhibitor Initiation in Acute Decompensated Heart Failure with Reduced Ejection Fraction: A Multi-Specialty Clinical Consensus

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated significant benefits in chronic heart failure with reduced ejection fraction (HFrEF) and, more recently, in acute decompensated heart failure (ADHF). However, practical guidance regarding their initiation during ADHF hospitalization, particularly in patients with concomitant renal impairment, remains a subject of clinical debate. This consensus paper synthesizes expert opinion on critical aspects of SGLT2 inhibitor use in this acute setting. Methods: This study utilized a community peer-review methodology facilitated by the tachyDx platform. A clinical scenario involving a 68-year-old female with ADHF-HFrEF and an eGFR of 32 mL/min/1.73m² was presented to a panel of four verified physicians (Cardiology, Nephrology, Internal Medicine). Their responses, addressing specific questions on eGFR thresholds, renal monitoring, AKI risk, and agent selection, were subjected to peer voting by 89 community physicians, establishing a consensus-driven framework. Results: Consensus emerged for SGLT2 inhibitor initiation at eGFR thresholds as low as 20-25 mL/min/1.73m², provided hemodynamic stability and euvolemia are achieved. Renal function monitoring at 48 hours and 7 days post-initiation was recommended, with an expected initial eGFR dip of 3-5 mL/min. The perceived risk of acute kidney injury (AKI) was primarily attributed to volume depletion rather than direct drug effect, necessitating concomitant loop diuretic dose reduction (20-30%). Full-dose initiation was advocated once patients were stable (off vasopressors/inotropes for 24 hours, stable diuretics). Euglycemic diabetic ketoacidosis was identified as a rare but significant concern, particularly in nutritionally compromised patients. Conclusions: This multi-specialty consensus supports the early initiation of SGLT2 inhibitors in hemodynamically stable ADHF-HFrEF patients, even with moderate renal impairment, emphasizing careful volume management and renal monitoring. These findings provide practical, evidence-informed guidance for clinicians navigating the complexities of SGLT2 inhibitor use in the acute care setting.

4 contributors 89 votes 6 Apr 2026

TDX-2026-00001

Evidence-Based Framework for Vasopressor and Inotrope Sequencing in Septic Shock with Concurrent Right Ventricular Failure: A Community Peer-Reviewed Clinical Consensus

Background: Septic shock frequently leads to complex hemodynamic instability, often complicated by acute right ventricular (RV) failure. This co-occurrence significantly increases morbidity and mortality, presenting a therapeutic challenge due to the intricate interplay between systemic vasodilation, elevated pulmonary vascular resistance (PVR), and myocardial dysfunction. Optimal vasopressor and inotropic agent sequencing in this specific clinical scenario remains a subject of ongoing debate and lacks definitive guideline recommendations. Methods: This consensus paper synthesizes expert opinions from a clinical Q&A discussion hosted on a specialized physician peer-review platform. Five verified critical care and cardiology specialists contributed to the discussion, which garnered 130 community peer votes. The methodology involved a structured analysis of proposed treatment algorithms, evaluation of supporting evidence, and identification of key monitoring parameters to establish a practical, stepwise approach. Results: A consensus emerged advocating for early initiation of vasopressin (0.03-0.04 U/min) as an adjunct to norepinephrine, prioritizing its favorable PVR profile over further norepinephrine escalation. Low-dose dobutamine (2.5-5 mcg/kg/min) was recommended for targeted RV inotropic support once mean arterial pressure was stabilized. In cases of refractory RV dysfunction, inhaled epoprostenol (20-50 ng/kg/min) was endorsed for selective pulmonary vasodilation. Agents such as phenylephrine and milrinone were strongly discouraged due to their potential to exacerbate RV afterload or systemic hypotension, respectively. Conclusions: This consensus provides a structured, evidence-informed approach to vasopressor and inotrope sequencing in septic shock with concurrent RV failure. The recommendations emphasize a physiologically guided strategy, prioritizing agents that minimize RV afterload while supporting contractility, alongside vigilant hemodynamic and echocardiographic monitoring. This framework aims to guide clinicians in managing this high-risk patient population.

5 contributors 130 votes 6 Apr 2026
← PreviousPage 2 of 2

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1